Canadian drug developer Oncolytics Biotech Inc. said Tuesday that the U.S. National Cancer Institute will sponsor a midstage study of its experimental drug Reolysin as a potential treatment for patients with pancreatic cancer that has spread.
The company said the study will compare Reolysin plus the chemotherapy combination paclitaxel and carboplatin with patients who just receive carboplatin and paclitaxel alone. The trial, which will enroll about 70 patients, will study progression-free survival time.
The Cancer Institute, which is part of the National Institutes of Health, will sponsor the trial while Oncolytics supplies Reolysin. This is the fourth trial using Reolysin to be sponsored by the Institute. Other studies are measuring the drug in treating metastatic melanoma and ovarian cancer patients.
Reolysin also is being studied in a late-stage trial involving carboplatin and paclitaxel to treat head and neck cancers.